Overall impact
C (46)

Commentary

Cutera is an average overall performer. With a 'C' rating of 46.2 for overall impact (34th percentile compared to all companies), Cutera ranks 147th out of 155 industry peers, behind Hologic, American Shared Hospital Services, Accuray and 143 others, and ahead of Sebia, Austco Healthcare, Nova Eye Medical and 5 others. On top material causes for Cutera's industry (Healthcare Equipment), Cutera performs poorly in Disaster Readiness and Effective Aid (30.8 score), Accountable Institutions (24.9), Reduced Inequality (26.8) and 7 other causes where it received a 'D' or 'F' score. Cutera did not receive an 'A' rating on any cause.
Impact
Cause CUTR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
430
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
Ca, United States
Share classes
CUTR
Description
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designed to strengthen, firm, and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and to treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and a network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California. On March 5, 2025, Cutera, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Material causes
Ethos considers the following causes material for Cutera, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.